中航光電(002179.SZ):中航富士達獲核准公開發行不超1500萬股新股
格隆匯 6 月 30日丨中航光電(002179.SZ)公佈,公司控股子公司中航富士達科技股份有限公司(“中航富士達”)於2020年6月30日收到證監會下發的《關於核准中航富士達科技股份有限公司向不特定合格投資者公開發行股票的批覆》(證監許可[2020]1301號),證監會核准中航富士達向不特定合格投資者公開發行不超過1500萬股新股,該批覆自核準發行之日起12個月內有效,中航富士達將按照證監會批覆文件要求及其股東大會的授權在規定期限內辦理本次向不特定合格投資者公開發行股票相關事宜。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.